X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (424) 424
humans (375) 375
anti-tnf (262) 262
infliximab (248) 248
rheumatology (236) 236
rheumatoid arthritis (221) 221
tumor necrosis factor-alpha - antagonists & inhibitors (216) 216
adalimumab (192) 192
female (185) 185
male (176) 176
etanercept (154) 154
antirheumatic agents - therapeutic use (147) 147
middle aged (145) 145
adult (141) 141
treatment outcome (136) 136
arthritis, rheumatoid - drug therapy (133) 133
anti-tnf therapy (129) 129
double-blind (120) 120
antibodies, monoclonal - therapeutic use (117) 117
arthritis (112) 112
therapy (107) 107
efficacy (100) 100
care and treatment (96) 96
tumor necrosis factor-tnf (96) 96
rheumatoid-arthritis (95) 95
safety (93) 93
crohn's disease (89) 89
crohns-disease (88) 88
inflammatory bowel disease (88) 88
patients (84) 84
ankylosing spondylitis (81) 81
tumor necrosis factor (80) 80
aged (79) 79
gastroenterology & hepatology (78) 78
immunology (75) 75
pharmacology & pharmacy (74) 74
ulcerative colitis (73) 73
medicine & public health (72) 72
antibodies, monoclonal, humanized - therapeutic use (68) 68
drug therapy (68) 68
methotrexate (68) 68
tumor-necrosis-factor (67) 67
rheumatoid factor (64) 64
psoriasis (63) 63
inflammatory-bowel-disease (59) 59
health aspects (58) 58
retrospective studies (56) 56
antirheumatic agents - adverse effects (54) 54
analysis (52) 52
anti-tnf-alpha (52) 52
dmards (52) 52
inflammatory bowel diseases - drug therapy (52) 52
monoclonal antibodies (51) 51
risk factors (51) 51
severity of illness index (51) 51
studies (51) 51
tnf inhibitors (49) 49
certolizumab pegol (48) 48
receptors, tumor necrosis factor - therapeutic use (48) 48
biologics (47) 47
immunoglobulin g - therapeutic use (47) 47
modifying antirheumatic drugs (47) 47
psoriatic arthritis (47) 47
ankylosing-spondylitis (46) 46
placebo-controlled trial (46) 46
treatment (46) 46
clinical-response (44) 44
disease (44) 44
biological products (41) 41
infliximab - therapeutic use (41) 41
spondylitis, ankylosing - drug therapy (41) 41
internal medicine (40) 40
monoclonal-antibody (40) 40
1506 (39) 39
antirheumatic agents (39) 39
immunogenicity (39) 39
necrosis-factor-alpha (39) 39
crohn disease - drug therapy (38) 38
rituximab (38) 38
anti-tnf agents (37) 37
medicine, research & experimental (37) 37
tumors (37) 37
adalimumab - therapeutic use (36) 36
animals (36) 36
drugs (36) 36
psoriatic-arthritis (36) 36
remission (36) 36
research (36) 36
usage (36) 36
inflammatory bowel diseases (35) 35
young adult (35) 35
antibodies, monoclonal - adverse effects (34) 34
clinical trials (34) 34
anti-inflammatory agents - therapeutic use (33) 33
clinical medicine (33) 33
medicine, general & internal (33) 33
tumor necrosis factor-alpha - immunology (33) 33
tumor necrosis factor-α (33) 33
methotrexate - therapeutic use (32) 32
rheumatic diseases (32) 32
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of the Rheumatic Diseases, ISSN 0003-4967, 02/2017, Volume 76, Issue 2, pp. 355 - 363
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 11/2013, Volume 72, Issue 11, pp. 1840 - 1844
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 2019, p. annrheumdis-2018-214994
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 12/2019, Volume 34, Issue 12, pp. 2090 - 2095
Background and Aim Vedolizumab (VDZ) has been used in inflammatory bowel disease (IBD) patients who failed anti‐tumor necrosis factor (TNF) therapy. This study... 
vedolizumab | anti‐TNF agents | switching therapy | inflammatory bowel disease
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 04/2019, Volume 78, Issue 4, pp. e23 - e23
Journal Article
Joint Bone Spine, ISSN 1297-319X, 10/2018, Volume 85, Issue 5, pp. 561 - 567
Objective: To explore acceptance and retention rate of biosimilar CT-P13 after switching from originator infliximab (OI) in patients with various rheumatic... 
Anti-TNF-alpha | Spondyloarthropathies | Patient attitude to health | DMARDs (biologics) | Rheumatoid arthritis | Ankylosing spondylitis | RHEUMATOID-ARTHRITIS | ANTIBODIES | INNOVATOR INFLIXIMAB | EFFICACY | SAFETY | RHEUMATOLOGY | IMMUNOGENICITY | PARALLEL-GROUP | DOUBLE-BLIND | CLASSIFICATION CRITERIA | Rheumatoid factor | Patient education | Arthritis | Infliximab
Journal Article
Autoimmunity Reviews, ISSN 1568-9972, 2011, Volume 10, Issue 7, pp. 397 - 403
Abstract The first approved biological agents for the treatment of rheumatoid arthritis (RA) were tumour necrosis factor (TNF) antagonists, all of which... 
Allergy and Immunology | Anti-TNF agents | Failure | Switching | NO RESPONSE | TNF INHIBITOR THERAPY | STURE REGISTRY | OPEN-LABEL | VICE-VERSA | IMMUNOLOGY | ANTITUMOR-NECROSIS-FACTOR | ALPHA ANTAGONISTS | INFLIXIMAB | ETANERCEPT | CLINICAL-PRACTICE | Clinical trials | Rheumatoid factor | Antirheumatic agents | Drug therapy | Rheumatoid arthritis
Journal Article